Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $39.5 million.

  • Kymera Therapeutics' Cash from Financing Activities fell 84.25% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $288.3 million, marking a year-over-year decrease of 52.59%. This contributed to the annual value of $608.9 million for FY2024, which is 14424.12% up from last year.
  • According to the latest figures from Q3 2025, Kymera Therapeutics' Cash from Financing Activities is $39.5 million, which was down 83.92% from $245.7 million recorded in Q2 2025.
  • Kymera Therapeutics' Cash from Financing Activities' 5-year high stood at $353.8 million during Q1 2024, with a 5-year trough of -$206,000 in Q3 2023.
  • In the last 3 years, Kymera Therapeutics' Cash from Financing Activities had a median value of $1.9 million in 2023 and averaged $81.7 million.
  • Per our database at Business Quant, Kymera Therapeutics' Cash from Financing Activities slumped by 100.14% in 2023 and then spiked by 121,904.85% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Cash from Financing Activities (Quarterly) stood at $2.1 million in 2021, then declined by 4.92% to $2.0 million in 2022, then dropped by 0.97% to $1.9 million in 2023, then skyrocketed by 42.97% to $2.8 million in 2024, then crashed by 84.25% to $39.5 million in 2025.
  • Its Cash from Financing Activities stands at $39.5 million for Q3 2025, versus $245.7 million for Q2 2025 and $258,000 for Q1 2025.